Company will showcase new assay at the upcoming San Antonio Breast Cancer Symposium While mutations in the ESR1 gene are exceedingly rare in cancer patients prior to treatment, the use of endocrine ...

By Tarun Sai Lomte Scientists reveal how evolution within our own tissues can drive disease, protect cells, and uncover hidden therapeutic targets for future precision medicine. Somatic genomics ...

Researchers in the U.K. have overthrown the orthodox view that childhood cancers have a low mutation burden, opening up new drug targets and opportunities for repurposing existing therapies. In ...

After decades of fixating on mutations in nuclear DNA as the prime suspects in cancer development, researchers are increasingly peering into the cell’s powerhouse for clues. Mutations in mitochondrial ...

MINNEAPOLIS, Dec. 10, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Asuragen, a Bio-Techne brand, launched a highly sensitive ESR1 mutation monitoring assay. ESR1 ...